MAPT and Alzheimer disease: The goal of this article is, first, to gain a better understanding of the categories of “preclinical AD” and “being at risk for AD.” Should these asymptomatic states, in which evidence for Aβ accumulation and tau-pathology is present, be regarded as disease, or as a risk factor, or something else?